mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy

• Published in: DNA repair 2021-08, Vol.104, p.103142-103142, Article 103142
• Main Authors: Danesh Pazhooh, Romina, Rahnamay Farnood, Parnia, Asemi, Zatollah, Mirsafaei, Liaosadat, Yousefi, Bahman, Mirzaei, Hamed
• Format: Article
• Language: English
• Subjects: Cancer; DNA damage; DNA repair; mTOR; Therapy
• ISSN: 1568-7864; 1568-7856
• DOI: 10.1016/j.dnarep.2021.103142

[Display omitted] •The mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase.•DDR maintains genomic stability and provides an opportunity for treating tumors.•This paper discusses the involvement of the mTOR signaling pathway and its regulators in cancer development. The mammalian target of rapamycin (mTOR) is a conserved serine/threonine-protein kinase, comprising two subunit protein complexes: mTORC1 and mTORC2. In response to insult and cancer, the mTOR pathway plays a crucial role in regulating growth, metabolism, cell survival, and protein synthesis. Key subunits of mTORC1/2 catalyze the phosphorylation of various molecules, including eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), ribosomal protein S6 kinase β-1 (S6K1). The DNA damage response (DDR) maintains genomic stability and provides an opportunity for treating tumors with defects caused by DNA damaging agents. Many mTOR inhibitors are utilized for the treatment of cancers. However, several clinical trials are still assessing the efficacy of mTOR inhibitors. This paper discusses the role of the mTOR signaling pathway and its regulators in developing cancer. In the following, we will review the interaction between DDR and mTOR signaling and the innovative therapies applied in preclinical and clinical trials for treating cancers.